CDKL5 and postpartum depression: Three novel drugs have already been approved by the FDA: brexanolone (ZulressoTM) and zuranolone (ZurzuvaeTM) for the treatment of postpartum depression and ganaxolone (ZtalmyTM) for the treatment of CDKL5 deficiency disorder.